-
Je něco špatně v tomto záznamu ?
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
WL. Van der Kolk, AGJ. Van der Zee, BM. Slomovitz, PJW. Baldwin, HC. Van Doorn, JA. De Hullu, J. Van der Velden, KN. Gaarenstroom, BFM. Slangen, P. Kjolhede, M. Brännström, I. Vergote, CM. Holland, R. Coleman, EBL. Van Dorst, WJ. Van Driel, D....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- biopsie sentinelové lymfatické uzliny MeSH
- lidé MeSH
- lokální recidiva nádoru patologie MeSH
- lymfadenektomie škodlivé účinky MeSH
- lymfadenopatie * patologie MeSH
- lymfatické metastázy patologie MeSH
- lymfatické uzliny patologie chirurgie MeSH
- nádory vulvy * patologie MeSH
- sentinelová uzlina * patologie chirurgie MeSH
- spinocelulární karcinom * patologie MeSH
- třísla MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVE: Optimal management of the contralateral groin in patients with early-stage vulvar squamous cell carcinoma (VSCC) and a metastatic unilateral inguinal sentinel lymph node (SN) is unclear. We analyzed patients who participated in GROINSS-V I or II to determine whether treatment of the contralateral groin can safely be omitted in patients with a unilateral metastatic SN. METHODS: We selected the patients with a unilateral metastatic SN from the GROINSS-V I and II databases. We determined the incidence of contralateral additional non-SN metastases in patients with unilateral SN-metastasis who underwent bilateral inguinofemoral lymphadenectomy (IFL). In those who underwent only ipsilateral groin treatment or no further treatment, we determined the incidence of contralateral groin recurrences during follow-up. RESULTS: Of 1912 patients with early-stage VSCC, 366 had a unilateral metastatic SN. Subsequently, 244 had an IFL or no treatment of the contralateral groin. In seven patients (7/244; 2.9% [95% CI: 1.4%-5.8%]) disease was diagnosed in the contralateral groin: five had contralateral non-SN metastasis at IFL and two developed an isolated contralateral groin recurrence after no further treatment. Five of them had a primary tumor ≥30 mm. Bilateral radiotherapy was administered in 122 patients, of whom one (1/122; 0.8% [95% CI: 0.1%-4.5%]) had a contralateral groin recurrence. CONCLUSION: The risk of contralateral lymph node metastases in patients with early-stage VSCC and a unilateral metastatic SN is low. It appears safe to limit groin treatment to unilateral IFL or inguinofemoral radiotherapy in these cases.
Amsterdam University Medical Center Amsterdam the Netherlands
Cambridge University Hospitals NHS Foundation Trust Cambridge United Kingdom
Catharina Ziekenhuis Eindhoven the Netherlands
CHUM Université de Montréal Montréal Quebec Canada
Department of Obstetrics and Gynaecology European Cancer Institute Milan Italy
Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam the Netherlands
European Translational Oncology Prevention and Screening Institute University Innsbruck Austria
Jena University Hospital Friedrich Schiller University Jena Germany
Leeds Teaching Hospitals NHS Trust St James' University Hospital Leeds United Kingdom
Leiden University Medical Center Leiden the Netherlands
Leuven Cancer Institute Leuven Belgium
Linköping University Linköping Sweden
Maastricht University Medical Center Maastricht the Netherlands
Manchester University NHS Foundation Trust St Marys Hospital Manchester United Kingdom
Medical University Graz Graz Austria
Mount Sinai Medical Center Miami Beach FL United States of America
Nottingham University Hospitals NHS Trust Nottingham United Kingdom
Radboud University Medical Center Nijmegen the Netherlands
Sahlgrenska Academy University of Gothenburg Göteborg Sweden
St Josephs Hospital and Medical Center Phoenix AZ United States of America
Stephenson Cancer Center University of Oklahoma Oklahoma City OK United States of America
The University of Texas MD Anderson Cancer Center Houston TX United States of America
University Medical Center Groningen University of Groningen Groningen the Netherlands
University Medical Center Utrecht Utrecht the Netherlands
University of Toronto Toronto Ontario Canada
Women and Infants Hospital of Rhode Island Providence RI United States of America
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22033165
- 003
- CZ-PrNML
- 005
- 20230131150646.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ygyno.2022.07.017 $2 doi
- 035 __
- $a (PubMed)36085090
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Van der Kolk, W L $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 245 10
- $a Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe / $c WL. Van der Kolk, AGJ. Van der Zee, BM. Slomovitz, PJW. Baldwin, HC. Van Doorn, JA. De Hullu, J. Van der Velden, KN. Gaarenstroom, BFM. Slangen, P. Kjolhede, M. Brännström, I. Vergote, CM. Holland, R. Coleman, EBL. Van Dorst, WJ. Van Driel, D. Nunns, M. Widschwendter, D. Nugent, PA. DiSilvestro, RS. Mannel, MY. Tjiong, D. Boll, D. Cibula, A. Covens, D. Provencher, IB. Runnebaum, BJ. Monk, V. Zanagnolo, K. Tamussino, MHM. Oonk, all GROINSS-V I and II participants
- 520 9_
- $a OBJECTIVE: Optimal management of the contralateral groin in patients with early-stage vulvar squamous cell carcinoma (VSCC) and a metastatic unilateral inguinal sentinel lymph node (SN) is unclear. We analyzed patients who participated in GROINSS-V I or II to determine whether treatment of the contralateral groin can safely be omitted in patients with a unilateral metastatic SN. METHODS: We selected the patients with a unilateral metastatic SN from the GROINSS-V I and II databases. We determined the incidence of contralateral additional non-SN metastases in patients with unilateral SN-metastasis who underwent bilateral inguinofemoral lymphadenectomy (IFL). In those who underwent only ipsilateral groin treatment or no further treatment, we determined the incidence of contralateral groin recurrences during follow-up. RESULTS: Of 1912 patients with early-stage VSCC, 366 had a unilateral metastatic SN. Subsequently, 244 had an IFL or no treatment of the contralateral groin. In seven patients (7/244; 2.9% [95% CI: 1.4%-5.8%]) disease was diagnosed in the contralateral groin: five had contralateral non-SN metastasis at IFL and two developed an isolated contralateral groin recurrence after no further treatment. Five of them had a primary tumor ≥30 mm. Bilateral radiotherapy was administered in 122 patients, of whom one (1/122; 0.8% [95% CI: 0.1%-4.5%]) had a contralateral groin recurrence. CONCLUSION: The risk of contralateral lymph node metastases in patients with early-stage VSCC and a unilateral metastatic SN is low. It appears safe to limit groin treatment to unilateral IFL or inguinofemoral radiotherapy in these cases.
- 650 12
- $a spinocelulární karcinom $x patologie $7 D002294
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a třísla $7 D006119
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfadenektomie $x škodlivé účinky $7 D008197
- 650 _2
- $a lymfatické uzliny $x patologie $x chirurgie $7 D008198
- 650 12
- $a lymfadenopatie $x patologie $7 D000072281
- 650 _2
- $a lymfatické metastázy $x patologie $7 D008207
- 650 _2
- $a lokální recidiva nádoru $x patologie $7 D009364
- 650 12
- $a sentinelová uzlina $x patologie $x chirurgie $7 D000071036
- 650 _2
- $a biopsie sentinelové lymfatické uzliny $7 D021701
- 650 12
- $a nádory vulvy $x patologie $7 D014846
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Van der Zee, A G J $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a Slomovitz, B M $u Mount Sinai Medical Center, Miami Beach, FL, United States of America
- 700 1_
- $a Baldwin, P J W $u Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- 700 1_
- $a Van Doorn, H C $u Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
- 700 1_
- $a De Hullu, J A $u Radboud University Medical Center, Nijmegen, the Netherlands
- 700 1_
- $a Van der Velden, J $u Amsterdam University Medical Center, Amsterdam, the Netherlands
- 700 1_
- $a Gaarenstroom, K N $u Leiden University Medical Center, Leiden, the Netherlands
- 700 1_
- $a Slangen, B F M $u Maastricht University Medical Center+, Maastricht, the Netherlands
- 700 1_
- $a Kjolhede, P $u Linköping University, Linköping, Sweden
- 700 1_
- $a Brännström, M $u Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
- 700 1_
- $a Vergote, I $u Leuven Cancer Institute, Leuven, Belgium
- 700 1_
- $a Holland, C M $u Manchester University NHS Foundation Trust-St Marys Hospital, Manchester, United Kingdom
- 700 1_
- $a Coleman, R $u The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America
- 700 1_
- $a Van Dorst, E B L $u University Medical Center Utrecht, Utrecht, the Netherlands
- 700 1_
- $a Van Driel, W J $u Center of Gynecological Oncology Amsterdam, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- 700 1_
- $a Nunns, D $u Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
- 700 1_
- $a Widschwendter, M $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, University Innsbruck, Austria
- 700 1_
- $a Nugent, D $u Leeds Teaching Hospitals NHS Trust, St James' University Hospital, Leeds, United Kingdom
- 700 1_
- $a DiSilvestro, P A $u Women and Infants Hospital of Rhode Island, Providence, RI, United States of America
- 700 1_
- $a Mannel, R S $u Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, United States of America
- 700 1_
- $a Tjiong, M Y $u Amsterdam University Medical Center, Amsterdam, the Netherlands
- 700 1_
- $a Boll, D $u Catharina Ziekenhuis Eindhoven, the Netherlands
- 700 1_
- $a Cibula, D $u First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Covens, A $u University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Provencher, D $u CHUM, Université de Montréal, Montréal, Quebec, Canada
- 700 1_
- $a Runnebaum, I B $u Jena University Hospital, Friedrich Schiller University, Jena, Germany
- 700 1_
- $a Monk, B J $u St Josephs Hospital and Medical Center, Phoenix, AZ, United States of America
- 700 1_
- $a Zanagnolo, V $u Department of Obstetrics and Gynaecology, European Cancer Institute, Milan, Italy
- 700 1_
- $a Tamussino, K $u Medical University Graz, Graz, Austria
- 700 1_
- $a Oonk, M H M $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: m.h.m.oonk@umcg.nl
- 710 2_
- $a all GROINSS-V I and II participants
- 773 0_
- $w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 167, č. 1 (2022), s. 3-10
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36085090 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150642 $b ABA008
- 999 __
- $a ok $b bmc $g 1891747 $s 1184500
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 167 $c 1 $d 3-10 $e 20220907 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
- LZP __
- $a Pubmed-20230120
